Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature.

Cancers (Basel) · 2020 · PMC7696181 · PMID 33182657

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

2.4 months; hazard ratio 0.63; 95% CI 0.47‒0.84; p = 0.0016) and a nonsignificant trend toward improved OS (28.5 vs. 23.9 months), in spite of a 70% crossover to a trastuzumab-containing regimen on progression in the anastrozole arm.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.